Sam currently serves as VP and Head of International Business Development for Salubris Pharmaceuticals and its US subsidiary Salubris Biotherapeutics.  His responsibilities include sourcing, evaluation, and negotiation of licensing, strategic investment and acquisition opportunities originating outside of China.  Prior to joining Salubris, Sam worked for ten years in strategy consulting and transaction advisory services across several global firms including Simon-Kucher & Partners and IMS (now IQVIA), where he was a Senior Principal in the strategy consulting division and Managing Director of IMS Health Capital.  Sam’s commercial strategy engagements encompassed 18 of the top 25 pharmaceutical companies, and his transaction advisory work included financings, alliances and acquisitions collectively exceeding $2B USD.  Sam completed his B.A. in Biochemistry, Ph.D. in Molecular Biology and Post-Doctoral Fellowship in Gene Therapy and Translational Medicine at the University of Pennsylvania, where he focused principally on gene therapy during his 13 years of bench research.  Sam currently serves on the boards of GO Therapeutics and MedAlliance, and as a board observer at Mercator Medsystems.